First Versions of Generic Zyprexa Approved

To treat schizophrenia or bipolar disorder

MONDAY, Oct. 24 (HealthDay News) -- The first generic versions of Zyprexa (olanzapine) have been approved by the U.S. Food and Drug Administration to treat schizophrenia or bipolar disorder, the agency said Monday.

Olanzapine has a boxed label warning that the drug can cause death among elderly people who have psychosis due to confusion and memory loss, the FDA said in a news release. Other adverse reactions could include hyperglycemia, high cholesterol or triglycerides, and weight gain.

Schizophrenia is a brain disorder that affects about 1 percent of Americans, with symptoms including hearing voices, paranoia, being suspicious, and withdrawing from everyday life. Bipolar disorder includes symptoms such as unusual changes in mood, energy, and ability to perform daily tasks.

The agency said any generic drugs it approves are clinically equivalent to the brand-name versions in quality, strength, purity, and stability.

Approval to produce generic versions of olanzapine were given to: Dr. Reddy's Laboratories Ltd., Teva Pharmaceuticals USA, Apotex Inc. and Par Phamaceuticals Inc.

More information

The FDA has more about Zyprexa.

Copyright © 2011 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events